Alemtuzumab, a highly effective anti-CD52 monoclonal antibody for relapsing-remitting multiple sclerosis (RRMS), acts mainly through the depletion and subsequent repopulation of T and B lymphocytes. This evidence concerns the gene CD52 and relapsing-remitting multiple sclerosis.